Mental health issues affect a significant percentage of children and adolescents worldwide, with behavior problems being among the most prevalent. Behavior problems in adolescence can lead to behavior disorders, contributing to adverse health outcomes, disability, diminished quality of life, and even premature mortality.
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial | Psychedelic Finance
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment